Buying MDMA pills Positano

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Buying MDMA pills Positano

In Italy, you can buy many medications, both over-the-counter and prescription, at the pharmacy or farmacia. Most OTC drugs and vitamins are not available at the supermarket, though you can find basic first aid supplies at both. For OTC and prescription medications, look for the cross sign, usually illuminated in green, to locate a pharmacy. Your hotel front desk should be able to direct you to the nearest farmacia. If you're staying at an Airbnb or similar rental, be sure to ask your host when you check in. Most major cities have one or more hour pharmacies, though these are not nearly as common as in the U. More typical is the ' farmacia di torno ' concept, where pharmacies within a given area take turns staying open at night and on Sundays. It means you might have to go out of your way to find an open pharmacy after hours or on Sunday, but there's usually one available within a few miles. If you take prescription drugs, be sure to carry them with you in their original containers in your carry-on luggage when flying to Italy. Do not pack them in your checked luggage. If you're carrying over three ounces of liquid medicine, bring the prescription or doctor's note with you. You should also carry a copy of your prescriptions or list of the medicines you take the actual drug names, not the generic names in case you need to buy them in Italy. If you take medications that are essential for you to have, it's also a good idea to give the list to one of your traveling companions as well as someone back home who you can contact if you need to replace your prescription medicine. If you need medication while traveling in Italy , head to the farmacia not the drogheria, which is more of a grocery store. The pharmacist may be able to replace your prescription drugs for you if you need more for any reason, even if you don't have the original prescription. The exceptions will be opiates, narcotics or other closely regulated medications—these will be difficult to get refilled in Italy. The safest course of action is to bring your original prescription, the bottle or container with your name on it, and, for tightly controlled substances, a note from your doctor saying that you require these medications. You might want to bring these with you especially if there is a particular brand that you prefer. Other medications, like aspirin, will usually be about the same cost as in the United States. If you're feeling a little ill, the pharmacist may be able to give you advice, too. There are English-speaking pharmacists in most major Italian cities. If you have a minor health problem and explain your symptoms, a pharmacist will usually recommend an OTC product. OTC medications are not usually on display, so you will probably have to ask the pharmacist for assistance. They may not have exactly the same medicine you are used to taking. The pharmacist will usually be able to find something equivalent to give you that will meet your needs. Other essentials that you'll easily find in a pharmacy are contact lens solutions you can also get these at a store that sells eyeglasses , sunscreen, mosquito spray, vitamins, toothpaste and mouthwash, feminine products, items for your baby, and sometimes even foods for special diets such as gluten-free pasta. There, an Italian doctor will be able to write you a prescription, assuming you can verify the medications you are currently taking. Whether you go to the ER or to a pharmacy, remember to always bring along your passport or other photo ID. Use limited data to select advertising. Create profiles for personalised advertising. Use profiles to select personalised advertising. Create profiles to personalise content. Use profiles to select personalised content. Measure advertising performance. Measure content performance. Understand audiences through statistics or combinations of data from different sources. Develop and improve services. Use limited data to select content. List of Partners vendors. Europe Italy More to Explore Essentials. By Martha Bakerjian. Martha Bakerjian. Martha Bakerjian is an Italian travel expert who uses her home in northern Tuscany as a base for her in-depth explorations of the country. Travel's editorial guidelines. Was this page helpful? Thanks for your feedback! Tell us why! Related Articles. Newsletter Sign Up. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data.

Where and How to Buy Medications in Italy

Buying MDMA pills Positano

Our aerospace and defense experts help industry players navigate their day-to-day operations and identify ways they can innovate for the future. Breakthroughs in automotive technologies and emerging business models are changing the world. We help the leading game changers stay ahead of the curve. Brands around the world must master digital to survive. We have the expertise and capabilities to power consumer-centric innovation grounded in data, analytics, and AI. We partner with effective organizations and educators to improve student outcomes and learning models—from K through higher education—locally, nationally, and globally. BCG helps global and regional financial institutions build for the future using digital innovations and an ESG focus to drive fundamental change and deliver on evolving customer demands. We work with organizations around the globe to transform health care operating models enabling them to deliver medical breakthroughs, innovative cures, and transformative patient experiences. Our experts provide industrial goods clients with the skills they need to adapt to change and rethink their business models in their rapidly evolving industries. Customers increasingly expect more from insurers. BCG helps companies rise to the challenge and equips them to lead in the digital future. The rapid growth of private capital brings unprecedented opportunities to unlock value while making a positive difference in the world. BCG advises leading investors on how to stay ahead. We help the world's leading retailers compete in the digital era by developing and delivering cutting-edge tech strategies and identifying new sources of growth. BCG collaborates with technology, media, and telecommunications companies to solve problems and pursue new strategies as they continue to shape the future. We empower clients to boldly reinvent themselves and embrace digital innovation so they can better serve their customers amid today's volatility. The industry has suffered an unprecedented shock. BCG collaborates with travel and tourism providers as they navigate this turbulence and build resilience for the future. Scaling artificial intelligence can create a massive competitive advantage. Learn how our AI-driven initiatives have helped clients extract value. Excavating purpose is among the rewarding journeys companies can take. BCG BrightHouse helps organizations embrace purpose to achieve higher returns, employee engagement, and customer satisfaction. Leaders face an uncertain landscape. The impact of each decision feels impossible to predict, which is why they need strategies that are proactive, resilient, and competitive. No matter their starting point, BCG can help. Even today's leading companies could benefit from an always-on transformation capability—the kind that engenders resilience and leads to long-term value creation. BCG knows what it takes to build this muscle. The time for global climate action is now. BCG helps clients accelerate their climate and sustainability journey and seize new opportunities to build competitive advantage. The rules of business and for maintaining competitive advantage are changing. We help companies reimagine strategy and value creation in a fast-paced world. Having rich customer insights allows companies to solve pressing business problems and capture growth opportunities. BCG identifies and delivers high-impact programs to build companies of the future that will outperform the competition in the future. Our work enables clients to build teams that fully reflect the diversity in the world and the communities they serve—and empowers them to advance their businesses and our society. Innovation is extremely difficult—but also necessary. We collaborate closely with organizations on holistic innovation journeys to help them secure long-term competitive advantage. We stand side by side with our clients, offering expertise and strategy as they look to expand the boundaries of their businesses in an uncertain and sometimes tumultuous world. We ask three guiding questions: when, where, and how will you manufacture in an era of emerging technologies and economic uncertainty? We're committed to helping our clients arrive at answers that are right for them. Customer centricity is key and made possible through analytics, agile processes, and a test-and-learn culture. BCG partners with marketing and sales organizations to make it happen. We help clients unlock value from every aspect of their operations, maximizing efficiency and effectiveness in procurement, service operations, supply chains, and beyond. Organization is at the core of nearly everything we do at BCG. We believe that when clients have the right organization design, the possibilities are endless. Any company's most important asset is its people. Our experts in leadership, culture, talent, reskilling, and HR help businesses respond to current and future challenges. We bring expertise and data-driven strategies to help clients unleash the power of effective pricing—and unlock its potential to increase the bottom line. BCG's Risk and Compliance consulting supports their client's growth ambition with strategic, transformational, and technical functional offerings in Finance. By focusing on tangible ways to generate positive social impact related to climate change, global education, racial equity, and more we help organizations tackle some of the most pressing issues facing our world today. Zero-based budgeting is a powerful strategy that yields significant benefits. Our approach fosters a culture of cost consciousness, growth, and innovation. A forward-thinking CEO agenda has never been more crucial. Our insights give you greater clarity on what lies ahead, helping you lead with confidence. We bring the ideas and inspiration that will help forward-looking leaders shape their next game. Subscribe to our newsletters and e-alerts to stay connected with the latest insights, data, ideas, and perspectives from BCG. As a top consulting firm, BCG helps clients with total transformation—driving complex change, enabling organizations to grow, and driving bottom-line impact. Related Expertise: Biopharma. Yet with competition growing increasingly cutthroat, the success of an entire product family can hinge on the gross margin of a SKU in a single market. Scale can help reduce small-molecule and biosimilar per-unit costs, but only to a point. Portfolio complexity has a huge impact, so companies need to monitor that complexity constantly. The key takeaway is clear. By carefully managing COGS, generic drug companies can improve their competitiveness dramatically. Our benchmark study explored the differences in the costs of producing generic small-molecule and biosimilar drugs. We also looked at the costs of producing different dosage forms of small-molecule products, in particular, oral solid doses OSDs and sterile liquids SLs. Three key findings emerged: COGS as a percentage of revenues varies widely; firms that produce both generic small-molecule and biosimilar drugs spend the same portion of COGS on the same functions; and both scale and complexity affect COGS. See Exhibit 1. These spans suggest that strategies and therefore profitability targets vary widely depending on where and how generics companies compete, and that the particular markets, portfolio mix, and pricing strategy all play a role, especially in the small molecule arena. Drilling down into the costs of producing generic small-molecule dosage forms, we found some important differences. Yet several generics players are keeping SLs—even products with negative margins—in their portfolio. We found that companies producing both generic small-molecule and biosimilar drugs end up spending the same portion of COGS on equivalent functions. Within small-molecule business units, the proportion of COGS spending devoted to internal and external manufacturing varies with the dosage form. These findings suggest that contract manufacturing plays a larger role in the production of hard-to-make products. For these reasons, some generics players have made the strategic decision not to develop the technical expertise or scale to derive any kind of competitive advantage from manufacturing SLs in-house. Outsourcing, in fact, helps remove unneeded complexity. The same considerations hold true for most biosimilar companies as well. For the small-molecule companies we analyzed, scale is the primary driver of COGS. That is, COGS is correlated to the volume per manufacturing site and total production volume, meaning the number of units produced in each business unit. Total Production Volume and Complexity. If OSD production volume exceeds a threshold of 30 billion to 40 billion units, unit costs start rising. The threshold for SL products is much lower—unit costs start rising after volume reaches only 1, million to 3, million units. See the sidebar for a comparison of the impact of scale on unit costs of small-molecule OSDs and their branded equivalents. In the case of OSDs, the per-unit cost starts rising when more than to SKUs are produced in one site because of factors such as frequent changeovers and complex planning. Local Champions. These companies have a strong commercial presence and access in a number of different specific markets, such as those in Europe, and so have a complex portfolio of products. Moreover, their manufacturing operations are located mostly in higher-cost domestic plants. Consequently, these firms have high unit costs. Players Based in India. Competing in select large markets while manufacturing a relatively simple portfolio in low-cost domestic locations, these companies have relatively low unit costs. Large Global Companies. Serving markets around the world, these companies produce a complex portfolio of products and are unable to fully leverage scale. Many of these firms have spent years rationalizing plants and optimizing their network footprint. As a result, their unit costs are moderate. The amount of portfolio complexity has a surprisingly significant impact on COGS. See Exhibit 3. Scale without streamlining will drive complexity up—and COGS along with it. To improve COGS performance, then, firms need to focus their efforts on managing the elements that demand the most spend—internal manufacturing and CMOs. The following practices are key:. This can be achieved with close collaboration between commercial and technical operations. See the sidebar. But because of the specific needs of different markets these companies serve, reducing complexity will likely be more difficult. We compared the per-unit costs of generic small-molecule and biopharma products along three dimensions:. These findings indicate that scale effects have a greater impact on small-molecule OSD unit costs than on the biopharma equivalents. By expanding to additional markets, they will naturally increase the complexity of their portfolios. But low labor costs will be insufficient to maintain their cost advantage: these firms will have to boost their operational efficiency as well. These are fairly broad recommendations. We recommend setting up regular joint reviews by commercial and technical operations organizations to eliminate product families or molecules that are not strategic, profitable, or necessary for the sales of other products. Key country, regional, or global organizations should manage the tradeoffs between markets. Reevaluate the internal production network. Companies should keep production in-house if there is a competitive advantage such as scale, access to a specific technology, or IP that must be protected. If players decide to take this route, they should focus on improving production costs with operational excellence measures. Best-practice companies tend to group their contract manufacturers into three or four tiers. The top tier consists of the few CMOs that are strategic partners, while the bottom tier is usually a long tail of one-off outsourcing projects for a specific product or market. For example:. Strategic Partnerships. Strategic alliances are essential for biopharma manufacturing. They are also becoming more important for small-molecule and biosimilar drug producers, which need access to the complex and expensive technologies and processes such as mechanisms to improve how a drug is delivered or how long it lasts. Toll Manufacturing. CDMO Partnerships. For all other molecules, partnerships with contract development manufacturing organizations are a good option if a company does not possess the needed capabilities internally. The cost pressures that generic and biosimilar drug companies feel today are unlikely to diminish any time soon. Their competitiveness depends on it. Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact. Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place. For information or permission to reprint, please contact BCG at permissions bcg. To find the latest BCG content and register to receive e-alerts on this topic or others, please visit bcg. Our Services. Industries Learn how we draw on industry expertise to make companies more competitive. Aerospace and Defense. Visit Page. Automotive Industry. Consumer Products Industry. Financial Institutions. Health Care Industry. Industrial Goods. Insurance Industry. Principal Investors and Private Equity. Public Sector. Retail Industry. Technology, Media, and Telecommunications. Transportation and Logistics. Travel and Tourism. Within Travel and Tourism Airline Industry. Capabilities See how we help our clients expand their capabilities on multiple existing—and emerging—fronts. Artificial Intelligence. Business and Organizational Purpose. Business Resilience. Business Transformation. Climate Change and Sustainability. Corporate Finance and Strategy. Cost Management. Customer Insights. Digital, Technology, and Data. Diversity, Equity, and Inclusion. Innovation Strategy and Delivery. International Business. Within Manufacturing Industry 4. Marketing and Sales. Organization Strategy. People Strategy. Pricing and Revenue Management. Risk Management and Compliance. Social Impact. Zero-Based Budgeting. BCG X. Our Insights. Latest Thinking. Explore a cross-section of the latest insights and perspectives from BCG experts. The CEO Agenda. BCG Henderson Institute. My Subscriptions. BCG Alumni. Our Company. People and Culture. Visit our media center for resources, press releases, trending topics, contacts, and more. Beyond Is Where We Begin. Explore Careers. Copy Shareable Link. The span between average top quartile and median companies is higher for small molecules than for biosimilars 13 and 9 percentage points, respectively. Companies producing both generic small-molecule and biosimilar drugs spend the same portion of COGS on equivalent functions. To improve COGS performance, firms need to focus on managing the elements that demand the most spend. The following practices are key: Improve visibility into costs. Getting a detailed, dynamic understanding of costs and allocations is critical for strategic decision making. Following the practices of a select few pharma companies, generic drug companies should leverage artificial intelligence and other digital technologies, which can more accurately allocate cost and revenue to each SKU. Commercial and technical operations can use this information to make better decisions about pricing, cost reduction, service optimization, and outsourcing for products throughout their life cycle. Manage volume-complexity tradeoffs. Volume per Site. All rights reserved. Subscribed Click to Manage Your Subscriptions.

Buying MDMA pills Positano